Plus   Neg

Ophthotech Corp. (OPHT) Soared Higher After Novartis Licensing Agreement

Ophthotech Corp. (OPHT) announced after the bell Monday that it has entered into an ex-US licensing and commercialization agreement with Novartis Pharmaceuticals focused on the treatment of wet age-related macular degeneration. Ophthotech has granted Novartis exclusive rights to commercialize Fovista in markets outside the United States.

Ophthotech gapped open sharply higher Tuesday morning, but traded in a range for the majority of the session. The stock finished up by 7.70 at $39.16, with volume at nearly an 8-month high. Ophthotech surged to a 2 1/2 month high.

by RTTNews Staff Writer

For comments and feedback: editorial@rttnews.com

Business News

Follow RTT